Biogen Reassessing Gene Therapy From Nightstar Deal After Phase II/III Miss

 
• By Joseph Haas
  
Gene therapy
An ocular gene therapy obtained by Biogen missed its endpoint in Phase II/III

More from Clinical Trials

More from R&D